期刊文献+

尘螨变应原Der f 2编码基因重组pCold TF体系构建及可溶性表达 被引量:7

Construction and solvable expression of the recombinant plasmid pCold TF-Der f 2 of Dermatophagoides farinae
原文传递
导出
摘要 目的建立尘螨变应原Der f 2编码基因重组pCold TF体系并诱导表达。方法以质粒pMD19-T-Der f 2为模板扩增目的基因Der f 2,克隆至pCold TF DNA载体,转化BL21细菌,用IPTG诱导表达,用SDS-PAGE和West-ern blot鉴定表达产物。结果 PCR扩增获得Der f 2编码基因,成功构建表达质粒pCold TF-Der f 2。SDS-PAGE检测表明该质粒在大肠埃希菌中正常表达,且基本为可溶性表达,表达产物分子质量单位为69ku,Western blot检测该蛋白能被鼠抗Penta-His抗体识别。结论成功建立尘螨变应原Der f 2编码基因重组pCold TF体系,并实现其可溶性原核表达。 Objective To construct and express the recombinant plasmid pCold TF-Der f 2 of Dermatophagoides farinae.Methods Using the plasmid pMD19-T-Der f 2 as template,the target gene Der f 2 was amplified by polymerase chain reaction.The gene fragment coding for Der f 2 was inserted into the prokaryotic expression plasmid pCold TF DNA to construct pCold TF-Der f 2 and transformed into E.coli BL21 for protein expression induced by isopropyl β-D-1-thiogalactopyranosid(IPTG).The expression product was analyzed and identified by SDS-PAGE and Western blotting.Results The gene coding for Der f 2 was obtained by PCR and the expression plasmid pCold TF-Der f 2 was successfully constructed.SDS-PAGE showed that the plasmid pCold TF-Der f 2 was successfully expressed in E.coli BL21.Most of the products are soluble and can bind with mouse anti-penta-His antibody according to Western blotting.Conclusion The recombinant plasmid pCold TF-Der f 2 of D.farinae was successfully constructed and highly expressed in E.coli,and the expressed fusion protein is soluble.
出处 《中国病原生物学杂志》 CSCD 北大核心 2012年第2期118-120,123,共4页 Journal of Pathogen Biology
基金 国家自然科学基金项目(No.30660166 NSFC81001330) 盐城市科技发展计划项目(No.YK2008079) 江苏省卫生厅招标课题(No.Z200914) 江苏省卫生职业技术教育研究立项课题(No.J200907) 江苏省"六大人才高峰"第六批资助项目
关键词 粉尘螨 变应原(Der F 2) 基因重组 原核表达 Dermatophagoides farinae allergen(Der f 2) genetic construction prokaryotic expression
  • 相关文献

参考文献11

  • 1Inerot S, Heinegard D, Olsson SE, et al. Proteoglycan alterations during developing experimental osteoarthritis in a novel hip joint model. J Orthop Res 1991; 9:658 - 73
  • 2王海宁,陈文魁,李朝品,姜玉新.尘螨Ⅰ类变应原所致过敏性哮喘治疗的研究进展[J].中国病原生物学杂志,2010,5(3):231-234. 被引量:4
  • 3杨李,王运刚,崔玉宝.尘螨变应原免疫生物学研究进展[J].中国病原生物学杂志,2011,6(2):150-154. 被引量:26
  • 4张超,姜玉新,李朝品.螨性哮喘特异性免疫治疗机制研究进展[J].中国病原生物学杂志,2010,5(4):313-316. 被引量:3
  • 5Karin H, Lisbet C, Staffan J, et al. Chondrocyte and chondrosarcoma cell integrins with affinity for collagen type Ⅱ and their response to mechanical stress. Exp Cell Res 1995; 221:496 - 503
  • 6Hus SM, Raine L, Franger H. Use of avidin-biotin-peroxidase complex(ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29:577 - 80
  • 7Dupuis H, Zerlett G. Beanspruchung des Menschen durch mechanische Schwingungen. Hrsg. Bonn/Berlin: Hauptverband der gewerblichen Berufsgenossenschaften 1984:17 - 60
  • 8冯萌,程训佳.螨性过敏性疾病的免疫治疗研究进展[J].中国病原生物学杂志,2009,4(12):949-951. 被引量:2
  • 9Dinakar C,Portnoy JM.Allergen immunotherapy in the preven-tion asthma[J].Curt Opin Allergy Clin Immunol,2004,4(2):131-6.
  • 10Taylor W, Pelmear PL, Pearson JCG. Raynaud's phenomenon of occupational origin. An epidemiological survey. Acta Chir Scand (Suppl) 1976; 465:27 - 32

二级参考文献102

  • 1朱万春,诸葛洪祥.粉螨性哮喘发病机制研究进展[J].环境与健康杂志,2007,24(3):184-186. 被引量:16
  • 2Weghofer M,Thomasw WR,Pittner G, et al. Comparison of purified Derrnatophagoides pteronyssinus allergens and extract by two-dimensional immunoblotting and quantitative immunoglobulin E inhibitions[J]. Clin Exp Allergy, 2005,35 : 1384-- 1391.
  • 3From the Global Strategy for Asthma Management and Prevention,Global Initiative for Asthma (GINA) 2006[OL]. Available from.. http..//www, ginasthma, org.
  • 4GINA reports: Global Burden of Asthma[OL]. Available on www. ginasthma, org.
  • 5Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen specific immunotherapy [ J ]. Allergy, 2006, 61 (82Suppl) : 1--20.
  • 6Tighe H, Takabayashi K, Raz E, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity[J]. J Allergy Clin Immunol,2000,106(1 Pt 1) :124--134.
  • 7Tulic MK,Fiset PO,Christodoulopoulos P.et al. Amb a 1 immu nostimulatory oligodeoxynueleotide conjugate immunotherapy decreases the nasal inflammatory response[J]. J Allergy Clin Immunol,2004,113:235--241.
  • 8Hochhaus G, Brookman L, Fox H, et al. Pharmacodynamics of omalizumab:implications for optimized dosing strategies and clinical efficacy in the treatment of allergic asthma[J]. Curt Med Res Opin, 2003,19 : 491 -- 498.
  • 9Busse W,Corren J, I.anier BQ, et al. Orualizumab, anti-IgE recombinant humanized monoclonal antibody,for the treatment of severe allergic asthma[J]. J Allergy Clin Immunol, 2001,108 : 184-- 190.
  • 10Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma[J]. Eur Respir J,2002,20:73--78.

共引文献28

同被引文献64

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部